journal article·2023Open access

Chitosan-coated ultrapure silicon nanoparticles produced by laser ablation: biomedical potential in nano-oncology as a tumor-targeting nanosystem

Tarek Baati, Imen Chaabani, Abir Salek, Leila Njim, Mouna Selmi, Ahmed Al-Kattan, Karim Hosni

Nanoscale Advances· Volume 5· Issue 11

Abstract

Ultrapure silicon nanoparticles (SiNPs) produced by femtosecond laser ablation in water have attracted great interest in the area of cancer therapy as they are efficient as photosensitizers in photodynamic therapy modality and can induce cell hyperthermia under radiofrequency radiation. Recently, we showed that these biocompatible nanoparticles were not able to reach tumors after intravenous injection in mice due to their rapid clearance from the bloodstream. In order to increase their half-life time and therefore their chances to reach and accumulate in tumors by an enhanced permeation retention (EPR) effect, a capping agent on SiNP surface acting as a colloidal stabilizer suspension is required. In this regard, this work focuses for the first time on the functionalization of SiNPs through the modification of their surface by chitosan (SiNPs-CH) in order to enhance their therapeutic properties in cancer therapy. Here, in vivo experiments were carried out during 15 days on nude mice developing a subcutaneously grafted malignant human brain tumor (glioblastoma). The characterization of SiNPs-CH showed an average hydrodynamic size of around 142 ± 65 nm as well as a relatively neutral charge (-5.2 mV) leading to a high colloidal suspension stability. The point of our work concerns the improvement of the biodistribution of SiNPs-CH with regard to tumors, the bloodstream, and organs. After the intravenous administration of 20 mg kg-1, all the studied parameters (animal behavior, organs' morphology, and histopathology) were in accord with the absence of toxicity due to SiNPs-CH, confirming their biocompatibility and even size and surface charge were modified compared to bare nanoparticles. Moreover an increased time in the bloodstream circulation of up to 7 days was observed, indicating the stealth of the nanoparticles, which could escape opsonization and premature elimination by macrophages and the reticuloendothelial system. As evidenced by silicon assessment, the interaction of the SiNPs-CH with the liver and spleen was significantly reduced compared to the bare nanoparticles. At the same time, SiNPs-CH were concentrated progressively in tumors from 12.03% after 1 day up to 39.55% after 7 days, confirming their uptake by the tumor microenvironment through the enhanced permeability retention effect. Subsequently, the silicon level declined progressively down to 33.6% after 15 days, evidencing the degradation of pH-sensitive SiNPs-CH under the acidic tumor microenvironment. Taken together, the stealthy SiNPs-CH exhibited an ideal biodistribution profile within the tumor microenvironment with a sustainable biodegradation and elimination profile, indicating their promising application in the nano-oncology field as a tumor-targeting system.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Laser-Ablation Synthesis of Nanoparticles · Silicon Nanostructures and Photoluminescence · Diamond and Carbon-based Materials Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Laboratoire des Substances Naturelles, Institut National de Recherche et d'Analyse Physico-chimique, Biotechpôle Sidi Thabet, 2020, Tunisia

Service de radiologie, Clinique Hospitalo-Universitaire de Médecine Dentaire, 5000 Monastir, Tunisia

Service d'Anatomie Pathologique, EPS Fattouma Bourguiba de Monastir, Faculté de Médecine de Monastir, Université de Monastir, 5000, Tunisia

Aix-Marseille University, CNRS, LP3 UMR 7341, Campus de Luminy, Case 917, CEDEX 09, 13288 Marseille, France

Funding

Ministère de l’Enseignement Supérieur et de la Recherche Scientifique

References (75)

Show source-provided references
1. Siegel · CA Cancer J. Clin. · 2020 · 70 · 710.3322/caac.21590 ↗
2. Ross · Am. J. Clin. Pathol. · 2004 · 122 · 59810.1309/5CWPU41AFR1VYM3F ↗
3. Misra · Drug Discovery Today · 2010 · 15 · 84210.1016/j.drudis.2010.08.006 ↗
4. Danhier · J. Controlled Release · 2010 · 148 · 13510.1016/j.jconrel.2010.08.027 ↗
5. Acharya · Adv. Drug Deliv. Rev. · 2011 · 63 · 17010.1016/j.addr.2010.10.008 ↗
6. Dadwal · Artif. Cells Nanomed. Biotechnol. · 2018 · 46 · 29510.1080/21691401.2018.1457039 ↗
7. Kalyane · Mater. Sci. Eng. C · 2019 · 98 · 125210.1016/j.msec.2019.01.066 ↗
8. Farokhzad · ACS Nano · 2009 · 3 · 1610.1021/nn900002m ↗
9. Eloy · Colloids Surf. B · 2016 · 141 · 7410.1016/j.colsurfb.2016.01.032 ↗
10. Devalapally · Int. J. Cancer · 2007 · 121 · 183010.1002/ijc.22886 ↗
11. Fan · Biomaterials · 2010 · 31 · 563410.1016/j.biomaterials.2010.03.066 ↗
12. Vaupel · Cancer Res. · 1989 · 49 · 6449
13. Cuvier · Biochem. Pharmacol. · 1992 · 44 · 50910.1016/0006-2952(92)90443-M ↗
14. Wojtkowiak · Cancer Res. · 2012 · 72 · 393810.1158/0008-5472.CAN-11-3881 ↗
15. Luo · Curr. Drug Metab. · 2013 · 14 · 87910.2174/138920021131400110 ↗
16. Madani · Int. J. Nanomedicine · 2011 · 6 · 2963
17. Bianco · Curr. Opin. Chem. Biol. · 2005 · 9 · 67410.1016/j.cbpa.2005.10.005 ↗
18. Baati · RSC Adv. · 2016 · 6 · 10168810.1039/C6RA24569B ↗
19. Baati · RSC Adv. · 2022 · 12 · 595310.1039/D1RA08533F ↗
20. Kundu · J. Adv. Res. · 2019 · 18 · 16110.1016/j.jare.2019.02.036 ↗
21. Riley · Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. · 2017 · 9 · e144910.1002/wnan.1449 ↗
22. Cunha · Chem. Mater. · 2013 · 25 · 276710.1021/cm400798p ↗
23. Baati · Sci. Rep. · 2016 · 6 · 2540010.1038/srep25400 ↗
24. Li · ACS Appl. Mater. Interfaces · 2017 · 9 · 212310.1021/acsami.6b13876 ↗
25. Wang · Nanomedicine · 2015 · 11 · 31310.1016/j.nano.2014.09.014 ↗
26. Salonen · Chem. Eng. J. · 2008 · 137 · 16210.1016/j.cej.2007.09.001 ↗
27. Jugdaohsingh · J. Nutr. Health Aging · 2007 · 11 · 99
28. Coffer · Phys. Status Solidi A · 2003 · 197 · 33610.1002/pssa.200306520 ↗
29. Vaccari · Microelectron. Eng. · 2006 · 83 · 159810.1016/j.mee.2006.01.113 ↗
30. Gu · Nat. Commun. · 2013 · 4 · 232610.1038/ncomms3326 ↗
31. Tilley · Adv. Mater. · 2006 · 18 · 205310.1002/adma.200600118 ↗
32. Yu · Nanotechnology · 2006 · 17 · 396210.1088/0957-4484/17/15/059 ↗
33. Heintz · Adv. Mater. · 2007 · 19 · 398410.1002/adma.200602752 ↗
34. Sugimoto · J. Phys. Chem. C · 2013 · 117 · 1185010.1021/jp4027767 ↗
35. Sangghaleh · ACS Nano · 2015 · 9 · 709710.1021/acsnano.5b01717 ↗
36. Neiner · J. Am. Chem. Soc. · 2006 · 128 · 1101610.1021/ja064177q ↗
37. Al-Kattan · Nanomaterials · 2020 · 10 · 146210.3390/nano10081462 ↗
38. Tamarov · Sci. Rep. · 2014 · 4 · 703410.1038/srep07034 ↗
39. Rioux · J. Biomed. Opt. · 2009 · 14 · 02101010.1117/1.3086608 ↗
40. Fuller · Biomaterials · 2008 · 29 · 152610.1016/j.biomaterials.2007.11.025 ↗
41. Mailaender · Biomacromolecules · 2009 · 10 · 237910.1021/bm900266r ↗
42. Sayyid · ACS Sustainable Chem. Eng. · 2017 · 5 · 1037910.1021/acssuschemeng.7b02388 ↗
43. Ma · Environ. Toxicol. · 2018 · 33 · 109710.1002/tox.22581 ↗
44. Dubey · Mater. Today: Proc. · 2015 · 2 · 3575
45. Kasaai · Carbohydr. Polym. · 2008 · 71 · 49710.1016/j.carbpol.2007.07.009 ↗
46. Yen · Carbohydr. Polym. · 2009 · 75 · 1510.1016/j.carbpol.2008.06.006 ↗
47. Yin · Gene · 2016 · 576 · 18910.1016/j.gene.2015.09.080 ↗
48. Shukula · Int. J. Biol. Macromol. · 2013 · 59 · 4610.1016/j.ijbiomac.2013.04.043 ↗
49. Majeti · React. Funct. Polym. · 2000 · 46 · 110.1016/S1381-5148(00)00038-9 ↗
50. Zhao · Polymers · 2018 · 10 · 46210.3390/polym10040462 ↗
51. Pecora · J. Nanopart. Res. · 2000 · 2 · 12310.1023/A:1010067107182 ↗
52. A.Domard and M.Domard , «Chitosan: Structure–Properties Relationship and Biomedical Applications» , Polymeric Biomaterials , ed. S. Dumitriu , Marcel Dekker , 2001 , pp. 187–212
53. Yu · ACS Nano · 2012 · 6 · 228910.1021/nn2043803 ↗
54. Villanueva · Nanotechnology · 2009 · 20 · 11510310.1088/0957-4484/20/11/115103 ↗
55. Miller · Biochemistry · 1998 · 37 · 1287510.1021/bi980096y ↗
56. Bannunah · Mol. Pharm. · 2014 · 11 · 436310.1021/mp500439c ↗
57. Verma · Small · 2010 · 6 · 1210.1002/smll.200901158 ↗
58. Shang · J. Nanobiotechnology · 2014 · 12 · 510.1186/1477-3155-12-5 ↗
59. Izume · Biosci. Biotechnol. Biochem. · 1992 · 56 · 44810.1271/bbb.56.448 ↗
60. Yu · ACS Nano · 2012 · 6 · 228910.1021/nn2043803 ↗
61. Jin · ACS Nano · 2009 · 3 · 14910.1021/nn800532m ↗
62. Napierska · Part. Fibre Toxicol. · 2010 · 7 · 110.1186/1743-8977-7-39 ↗
63. Ernsting · J. Control. Release · 2013 · 172 · 78210.1016/j.jconrel.2013.09.013 ↗
64. Shin · Nanomaterials · 2015 · 5 · 135110.3390/nano5031351 ↗
65. Longmire · Nanomedicine · 2008 · 3 · 70310.2217/17435889.3.5.703 ↗
66. Fukumura · J. Cell. Biochem. · 2007 · 101 · 93710.1002/jcb.21187 ↗
67. Nagy · Semin. Thromb. Hemostasis · 2010 · 36 · 32110.1055/s-0030-1253454 ↗
68. Torchilin · Adv. Drug Deliv. Rev. · 2011 · 63 · 13110.1016/j.addr.2010.03.011 ↗
69. Torchilin · AAPS J. · 2007 · 9 · 12810.1208/aapsj0902015 ↗
70. Carmeliet · Nature · 2000 · 407 · 24910.1038/35025220 ↗
71. Carita · Curr. Med. Chem. · 2018 · 25 · 60610.2174/0929867324666171009120154 ↗
72. Sykes · ACS Nano · 2014 · 8 · 569610.1021/nn500299p ↗
73. Burbridge · Angiogenesis · 1999 · 3 · 28110.1023/A:1009092511894 ↗
74. Lim · Curr. Drug Targets · 2018 · 19 · 30010.2174/1389450117666160602202339 ↗
75. Kadry · Fluids Barriers CNS · 2020 · 17 · 6910.1186/s12987-020-00230-3 ↗